MEDIA CENTER

PRESS RELEASES
NEWS

Rapha Capital BioVentures Fund I Launches DELIVER Therapeutics Inc. with $3 Million Convertible Note Financing

DELIVER Therapeutics, Inc. (“DELIVER”) a company that plans to apply novel, high-throughput screening technologies combined with chemical innovation to DELIVER therapeutics that address the most difficult problems in clinical medicine has been launched with an initial $3M Convertible Note financing by Rapha Capital BioVentures Fund I, LP

Kevin Slawin In News

New use of screening technology finds SARS-CoV-2 treatment target in lab setting

Finding effective treatments for SARS-CoV-2, the viral agent responsible for COVID-19, has been difficult but researchers at Baylor College of Medicine are working to find a potential solution. Much attention...

Stapled Peptides

Danny Tetzl In Scientific Publications, Stapled Peptides

Solution-Phase Fmoc-Based Peptide Synthesis for DNA-Encoded Chemical Libraries: Reaction Conditions, Protecting Group Strategies, and Pitfalls

/wp-content/uploads/2021/12/MontyOB20.DECL_.Peptide.clean_.pdf

Danny Tetzl In Scientific Publications, Stapled Peptides

Homogeneous and Functional Group Tolerant Ring-Closing Metathesis for DNA-Encoded Chemical Libraries

/wp-content/uploads/2021/12/MontyOB20.DECL_.ring_.closing.pdf